Serum and Vitreous Levels of Placenta Growth Factor in Diabetic Retinopathy Patients: Correlation With Disease Severity and Optical Coherence Tomographic Parameters

• Published in: Curēus (Palo Alto, CA) CA), 2024-02, Vol.16 (2), p.e54862-e54862
• Main Authors: Mesquita, Joana, Santos, Fátima Milhano, Sousa, João Paulo, Vaz-Pereira, Sara, Tavares-Ratado, Paulo, Neves, Arminda, Mesquita, Rita, Tomaz, Cândida Teixeira
• Format: Article
• Language: English
• Subjects: Angiogenesis; Diabetes; Diabetic retinopathy; Endocrinology/Diabetes/Metabolism; Eye diseases; Inflammation; Ischemia; Kinases; Ophthalmology; Patients; Physiology; Retinal detachment; Surgery; Vascular endothelial growth factor; Wound healing
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.54862

Purpose The primary objective of this study was to compare placenta growth factor (PlGF) levels in the serum and vitreous of diabetic retinopathy (DR) patients to non-diabetic controls. Additionally, the study aimed to establish associations between serum and vitreous PlGF concentrations and to examine the correlation between vitreous PlGF in DR patients and morphological parameters. Methods This study included serum and vitreous samples from 38 patients, including 21 patients with DR and 17 non-diabetic controls. The control group included non-diabetic patients with rhegmatogenous retinal detachment with retinal tears secondary to posterior vitreous detachment or trauma. PlGF levels were quantified in vitreous and serum samples using an enzyme-linked immunosorbent assay (ELISA). Optical coherence tomography (OCT) scans from DR patients were evaluated to measure the central retinal thickness (CRT) and macular volume (MV). Results DR patients had significantly higher mean vitreous PlGF levels compared to non-DR patients (70.0±39.2 vs. 46.47±9.7 pg/mL, p-value=0.004). However, no significant increase in mean serum PlGF levels was observed in DR patients (p-value=0.232). Within the DR group, proliferative DR (PDR) patients presented significantly higher vitreous PlGF levels than non-PDR (NPDR) patients (76.5±41.0 vs. 42.5±5.0 pg/mL, p-value=0.009). There was no association between serum and vitreous PlGF levels. The correlation between vitreous PlGF levels and morphological parameters was r =0.175, p-value=0.488 for CRT, and r =0.288, p-value=0.262 for MV. Conclusion This study emphasizes the important role of PlGF in neovascularization, specifically highlighting its overexpression exclusively in vitreous from PDR patients. The observed increase in PlGF levels may be indicative of disease severity. The lack of correlation between vitreous and serum PlGF levels suggests a potential dissociation between intravitreal and systemic PlGF synthesis. Consequently, targeting PlGF in therapeutic approaches may offer an additional strategy for ocular pathologies with a neovascular component.